Cell survival and apoptosis signaling as therapeutic target for cancer: Marine bioactive compounds

International Journal of Molecular Sciences

Volumn 14, Issue 2, 2013, Pages 2334-2354

  Kalimuthu, Senthilkumar ^a   Se Kwon, Kim ^a  

^a Pukyong National University   (South Korea)

Author keywords

AKT; Apoptosis; Bax; Cell survival; Marine compounds

Indexed keywords

6 BROMOISATIN; ANTINEOPLASTIC AGENT; ARENAMIDE A; ARENAMIDE B; ARENAMIDE C; ASCIDIDEMIN; CHITOSAN; CHITOSAN DERIVATIVE; CRYPTOSPHAEROLIDE; DEATH RECEPTOR; DIETHYLAMINOETHYL CHITOSAN; FENRETINIDE; FUCOIDIN; HETERONEMIN; LAMELLARIN D; MAKALUVAMINE A; MARINE BIOACTIVE COMPOUND; NATURAL PRODUCT; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RALOXIFENE; SPONGISTATIN 1; STREPTOCHLORIN; TAMOXIFEN; TYRINDOLENINONE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BIOCOMPATIBILITY; BREAST CANCER; CANCER GROWTH; CANCER PREVENTION; CANCER RESEARCH; CARCINOGENESIS; CELL SURVIVAL; DNA DEGRADATION; DRUG CYTOTOXICITY; DRUG EFFICACY; ENZYME ACTIVITY; HIGH RISK PATIENT; HUMAN; INTRACELLULAR SIGNALING; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MARINE ENVIRONMENT; MOLECULAR INTERACTION; NONHUMAN; PHAGOCYTOSIS; PROTEIN CLEAVAGE; PROTEIN CROSS LINKING; REVIEW; SIGNAL TRANSDUCTION;

EID: 84875103424     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms14022334     Document Type: Review

References (126)

1. Lockshin, R.A.; Zakeri, Z. Cell death in health and disease. J. Cell. Mol. Med. 2007, 11, 1214-1224.
2. Duprez, L.; Wirawan, E.; Vanden Berghe, T.; Vandenabeele, P. Major cell death pathways at a glance. Microbes Infect. 2009, 11, 1050-1062.
3. Sprick, M.R.; Walczak, H. The interplay between the Bcl-2 family and death receptor-mediated apoptosis. Biochim. Biophys. Acta. 2004, 1644, 125-132.
4. Whelan, R.S.; Kaplinskiy, V.; Kitsis, R.N. Cell death in the pathogenesis of heart disease: Mechanisms and significance. Annu. Rev. Physiol. 2010, 72, 19-44.
5. Engelman, J.A. Targeting PI3K signaling in cancer: Opportunities, challenges and limitations. Nat. Rev. Cancer 2009, 9, 550-562.
6. Fulda, S.; Galluzzi, L.; Kroemer, G. Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov. 2010, 9, 447-464.
7. Parcellier, A.; Tintignac, L.A.; Zhuravleva, E.; Hemmings, B.A. PKB and the mitochondria: AKT signaling on apoptosis. Cell. Signal. 2008, 20, 21-30.
8. Shaw, R.J.; Cantley, L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441, 424-430.
9. Hsieh A.C.; Truitt, M.L.; Ruggero, D. Oncogenic AKT activation of translation as a therapeutic target. Br. J. Cancer 2011, 105, 329-336.
10. Yin, Y.; Shen, W.H. PTEN: A new guardian of the genome. Oncogene 2008, 27, 5443-5453.
11. Yamaguchi, H.; Wang, H.G. The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Baxc onformational change. Oncogene 2001, 20, 7779-7786.
12. Gardai, S.J.; Hildeman, D.A.; Frankel, S.K.; Whitlock, B.B.; Frasch, S.C.; Borregaard, N.; Marrack, P.; Bratton, D.L.; Henson, P.M. Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils. J. Biol. Chem. 2004, 279, 21085-21095.
13. Qi, X.J.; Wildey, G.M.; Howe, P.H. Evidence that Ser87 of Bim EL is phosphorylated by Akt and regulates BimEL apoptotic function. J. Biol. Chem. 2006, 281, 813-823.
14. Dan, H.C.; Sun, M.; Kaneko, S.; Feldman, R.I.; Nicosia, S.V.; Wang, H.G.; Tsang, B.K.; Cheng, J.Q. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J. Biol. Chem. 2004, 279, 5405-5412.
15. Maurer, U.; Charvet, C.; Wagman, A.S.; Dejardin, E.; Green, D.R. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol. Cell 2006, 21, 749-760.
16. Van Der Heide, L.P.; Hoekman, M.F.M.; Smidt, M.P. The ins and outs of FoxO shuttling: Mechanisms of FoxO translocation and transcriptional regulation. Biochem. J. 2004, 380, 297-309.
17. De Keizer, P.L.; Burgering, B.M.; Dansen, T.B. Forkhead boxo as a sensor, mediator and regulator of redox signaling. Antioxid. Redox Signal. 2011, 14, 1093-1106.
18. Ozes, O.N.; Mayo, L.D.; Gustin, J.A.; Pfeffer, S.R.; Pfeffer, L.M.; Donner, D.B. NF-kappa B activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999, 401, 82-85.
19. Romashkova, J.A.; Makarov, S.S. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999, 401, 86-90.
20. Bender, A.; Opel, D.; Naumann, I.; Kappler, R.; Friedman, L.; von Schweinitz, D.; Debatin, K.M.; Fulda, S. PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2proteins and enhanced mitochondrial apoptosis. Oncogene 2011, 30, 494-503.
21. Opel, D.; Naumann, I.; Schneider, M.; Bertele, D.; Debatin, K.M.; Fulda, S. Targeting aberrant PI3K/Akt activation by PI 103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma. Clin. Cancer Res. 2011, 17, 3233-3247.
22. Obexer, P.; Geiger, K.; Ambros, P.F.; Meister, B.; Ausserlechner, M.J. FKHRL1-mediated expression of Noxa and Bim induces apoptosis via the mitochondria in neuroblastoma cells. Cell Death Differ. 2007, 14, 534-547.
23. Ploner, C.; Kofler, R.; Villunger, A. Noxa: At the tip of the balance between life and death. Oncogene 2008, 27, 84-92.
24. Johnstone, R.W.; Ruefli, A.A.; Lowe, S.W. Apoptosis, a link between cancer genetics and chemotherapy. Cell 2002, 108, 153-164.
25. Fulda, S.; Debatin, K.M. Extrinsic versus intrinsic apoptosis pathways in anti cancer chemotherapy. Oncogene 2006, 25, 4798-4811.
26. Fulda, S.; Vucic, D. Targeting IAP proteins for therapeutic intervention in cancer. Nat. Rev. Drug Discov. 2012, 11, 109-124.
27. Levine, A. P53, the cellular gatekeeper for growth and division. Cell. Mol. Biol. 1997, 88, 323-331.
28. Yin, C.; Knudson, C.; Korsmeyer, S.; Dyke, T.V. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 1997, 385, 637-640.
29. Pietenpol, J.; Stewart, Z. Cell cycle checkpoint signaling, cell cycle arrest versus apoptosis. Toxicology 2002, 475, 181-182.
30. Johnson, T.; Yu, Z.; Ferrans, V.; Lowenstein, R.; Finkel, T. Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proc. Natl. Acad. Sci. USA 1996, 93, 11848-11852.
31. Sheikh, M.; Fornace, A.J. Role of p53 family members in apoptosis. J. Cell. Physiol. 2000, 182, 171-181.
32. Martindale, J.; Holbrook, N. Cellular response to oxidative stress, signaling for suicide and survival. J. Cell. Physiol. 2002, 192, 1-15.
33. Saelens, X.; Festjens, N.; Walle, L.V.; van Gurp, M.; van Loo, G.; Vandenabeele, P. Toxic proteins released from mitochondria in cell death. Oncogene 2004, 23, 2861-2874.
34. Du, C.; Fang, M.; Li, Y.; Li, L.; Wang, X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000, 102, 33-42.
35. Van Loo, G.; van Gurp, M.; Depuydt, B.; Srinivasula, S.M.; Rodriguez, I.; Alnemri, E.S.; Gevaert, K.; Vandekerckhove, J.; Declercq, W.; Vandenabeele, P. The serine protease Omi/HtrA2 is released from mitochondria during apoptosis. Omi interacts with caspase-inhibitor XIAP and induces enhanced caspase activity. Cell Death Differ. 2002, 9, 20-26.
36. Garrido, C.; Galluzzi, L.; Brunet, M.; Puig, P.E.; Didelot, C.; Kroemer, G. Mechanisms of cytochrome c release from mitochondria. Cell Death Differ. 2006, 13, 1423-1433.
37. Chinnaiyan, A.M. The apoptosome, heart and soul of the cell death machine. Neoplasia 1999, 1, 5-15.
38. Hill, M.M.; Adrain, C.; Duriez, P.J.; Creagh, E.M.; Martin, S.J. Analysis of the composition, assembly kinetics and activity of native Apaf-1 apoptosomes. EMBO J. 2002, 23, 2134-2145.
39. Schimmer, A.D. Inhibitor of apoptosis proteins, translating basic knowledge into clinical practice. Cancer Res. 2004, 64, 7183-7190.
40. Ekert, P.G.; Vaux, D.L. The mitochondrial death squad, hardened killers or innocent bystanders? Curr. Opin. Cell Biol. 2005, 17, 626-630.
41. Joza, N.; Susin, S.A.; Daugas, E.; Stanford, W.L.; Cho, S.K.; Li, C.Y.; Sasaki T.; Elia, A.J.; Cheng, H.Y.M.; Ravagnan, L.; et al. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature 2001, 410, 549-554.
42. Susin, S.A.; Daugas, E.; Ravagnan, L.; Samejima, K.; Zamzami, N.; Loeffler, M.; Costantini, P.; Ferri, K.F.; Irinopoulou, T.; Prévost, M.-C.; et al. Two distinct pathways leading to nuclear apoptosis. J. Exp. Med. 2000, 192, 571-580.
43. Li, L.Y.; Luo, X.; Wang, X. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 2001, 412, 95-99.
44. Enari, M.; Sakahira, H.; Yokoyama, H.; Okawa, K.; Iwamatsu, A.; Nagata, S. A caspase-activated DNase that degrades DNA during apoptosis and its inhibitor ICAD. Nature 1998, 391, 43-50.
45. Cory, S.; Adams, J.M. The Bcl2 family, regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2002, 2, 647-656.
46. Schuler, M.; Green, D.R. Mechanisms of p53-dependent apoptosis. Biochem. Soc. Trans. 2001, 29, 684-688.
47. Vaux, D.L.; Cory, S.; Adamsm, J.M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988, 335, 440-442.
48. Weyhenmeyer, B.; Murphy, A.C.; Prehn, J.H.; Murphy, B.M. Targeting the anti-apoptotic bcl-2 family members for the treatment of cancer. Exp. Oncol. 2012, 34, 192-199.
49. Tsujimoto, Y.; Finger, L.R.; Yunis, J.; Nowell, P.C.; Croce, C.M. Cloning of the chromosome breakpoint of neoplastic B cells with the t (14;18) chromosome translocation. Science 1984, 226, 1097-1099.
50. Reed, J.C. Bcl-2 family proteins, regulators of apoptosis and chemoresistance in hematologic malignancies. Semin. Hematol. 1997, 34, 9-19.
51. Portt, L.; Norman, G.; Clapp, C.; Greenwood, M.; Greenwood, T.M. Anti-apoptosis and cell survival: A review. Biochim. Biophys. Acta 2011, 1813, 238-259.
52. Reed, J.C. Bcl-2 and the regulation of programmed cell death. J. Cell. Biol. 1994, 124, 1-6.
53. Yip, K.W.; Reed J.C. Bcl-2 family proteins and cancer. Oncogene 2008, 27, 6398-6406.
54. Scorrano, L.; Korsmeyer, S. Mechanisms of cytochrome c release by proapoptotic BCL-2 family members. Biochem. Biophys. Res. Commun. 2003, 304, 437-444.
55. Korsmeyer, S.J. Regulators of cell death. Trends Genet. 1995, 11, 101-105.
56. Lee, H.J.; Lee, H.J.; Lee, E.O.; Ko, S.G.; Bae, H.S.; Kim, C.H.; Ahn, K.S.; Lu, J.; Kim, S.H. Mitochondria-cytochrome C-caspase-9 cascade mediates isorhamnetin-induced apoptosis. Cancer Lett. 2008, 207, 342-353.
57. Fiandalo, M.V.; Kyprianou, N. Caspase control: Protagonists of cancer cell apoptosis. Exp. Oncol. 2012, 34, 165-175.
58. Reed, J. Apoptosis-targeted therapies for cancer. Cancer Cell 2003, 3, 9-17.
59. Zapata, J.M.; Pawlowski, K.; Haas, E.; Ware, C.F.; Godzik, A.; Reed, J.C. A diverse family of proteins containing tumor necrosis factor receptor-associated factor domains. J. Biol. Chem. 2001, 276, 24242-24252.
60. Lamy, T.; Liu, J.H.; Landowski, T.H.; Dalton, W.S.; Loughran, T.P., Jr. Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3 large granular lymphocyte leukemia. Blood 1998, 92, 4771-4777.
61. Landowski, T.H.; Moscinski, L.; Burke, R.; Buyuksal, I.; Painter, J.S.; Goldstein, S.; Dalton, W.S. CD95 antigen mutations in hematopoietic malignancies. Leuk. Lymphoma 2001, 42, 835-846.
62. Krammer, P.H. CD95's deadly mission in the immune system. Nature 2000, 407, 789-795.
63. Wajant, H. The Fas signaling pathway, more than a paradigm. Science 2002, 296, 1635-1636.
64. Landowski, T.H.; Qu, N.; Buyuksal, I.; Painter, J.S.; Dalton, W.S. Mutations in the Fas antigen in patients with multiple myeloma. Blood 1997, 90, 4266-4270.
65. Irie, S.; Li, Y.; Kanki, H.; Ohyama, T.; Deaven, L.L.; Somlo, S.; Sato, T.A. Identification of two Fas-associated phosphatase-1 (FAP-1) promoters in human cancer cells. DNA Seq. 2001, 11, 519-526.
66. Krueger, A.; Baumann, S.; Krammer, P.H.; Kirchhoff, S. FLICE-inhibitory proteins, regulators of death receptor-mediated apoptosis. Mol. Cell. Biol. 2001, 21, 8247-8254.
67. Strasser, A.; O'Connor, L.; Dixit, V.M. Apoptosis signaling. Annu. Rev. Biochem. 2000, 69, 217-245.
68. Henson, P.M.; Bratton, D.L.; Fadok, V.A. Apoptotic cell removal. Curr. Biol. 2001, 11, 795-805.
69. Green, D.R.; Evan, G.I. A matter of life and death. Cancer Cell 2002, 1, 19-30.
70. Thornberry, N.A.; Lazebnik, Y. Caspases, enemies within. Science 1998, 281, 1312-1316.
71. Mancini, M.; Nicholson, D.W.; Roy, S.; Thornberry, N.A.; Peterson, E.P.; Casciola-Rosen, L.A.; Rosen, A. The caspase-3 precursor has a cytosolic and mitochondrial distribution, implications for apoptotic signaling. J. Cell Biol. 1998, 140, 1485-1495.
72. Hengartner, M.O. The biochemistry of apoptosis. Nature 2000, 407, 770-776.
73. Cohen, G.M. Caspases, the executioners of apoptosis. Biochem. J. 1997, 336, 1-16.
74. Rai, N.K.; Tripathi, K.; Sharma, D.; Shukla, V.K. Apoptosis, a basic physiologic process in wound healing. Int. J. Low Extrem. Wounds 2005, 4, 138-144.
75. Hu, S.; Snipas, S.J.; Vincenz, C.; Salvesen, G.; Dixit, V.M. Caspase-14 is a novel developmentally regulated protease. J. Biol. Chem. 1998, 273, 29648-29653.
76. Nakagawa, T.; Zhu, H.; Morishima, N.; Li, E.; Xu, J.; Yankner, B.A.; Yuan, J. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 2000, 403, 98-103.
77. Koenig, U.; Eckhart, L.; Tschachler, E. Evidence that caspase-13 is not a human but a bovine gene. Biochem. Biophys. Res. Commun. 2001, 285, 1150-1154.
78. Kang, S.J.; Wang, S.; Kuida, K.; Yuan, J. Distinct downstream pathways of caspase-11 in regulating apoptosis and cytokine maturation during septic shock response. Cell Death Differ. 2002, 9, 1115-1125.
79. Nemes, Z., Jr.; Friis, R.R.; Aeschlimann, D.; Saurer, S.; Paulsson, M.; Fésüs, L. Expression and activation of tissue transglutaminase in apoptotic cells of involuting rodent mammary tissue. Eur. J. Cell Biol. 1996, 70, 125-133.
80. Bortner, C.D.; Oldenburg, N.B.; Cidlowski, J.A. The role of DNA fragmentation in apoptosis. Trends Cell Biol. 1995, 5, 21-26.
81. Bratton, D.L.; Fadok, V.A.; Richter, D.A.; Kailey, J.M.; Guthrie, L.A.; Henson, P.M. Appearance of phosphatidylserine on apoptotic cells requires calcium-mediated nonspecific flip-flop and is enhanced by loss of the aminophospholipid translocase. J. Biol. Chem. 1997, 272, 26159-26165.
82. Arur, S.; Uche, U.E.; Rezaul, K.; Fong, M.; Scranton, V.; Cowan, A.E.; Mohler, W.; Han, D.K. Annexin I is an endogenous ligand that mediates apoptotic cell engulfment. Dev. Cell 2003, 4, 587-598.
83. Gardai, S.J.; McPhillips, K.A.; Frasch, S.C.; Janssen, W.J.; Starefeldt, A.; Murphy-Ullrich, J.E.; Bratton, D.L.; Oldenborg, P.-A.; Michalak, M.; Henson, P.M. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005, 123, 321-334.
84. Kuno, T.; Tsukamoto, T.; Hara, A.; Tanaka, T. Cancer chemoprevention through the induction of apoptosis by natural compounds. J. Biophys. Chem. 2012, 3, 156-173.
85. Fisher, B.; Perera, F.; Cooke, A.; Opeitum A, Stitt L. Long-term follow-up of axillary node-positive breast cancer patients receiving adjuvant tamoxifen alone, patterns of recurrence. Int. J. Radiat. Oncol. Biol. Phys. 1998, 42, 117-123.
86. Cummings, S.; Eckert, S.; Krueger, K.; Grady, D.; Powles, T.J.; Cauley, J.A.; Norton, L.; Nickelsen, T.; Bjarnason, N.H.; Morrow, M.; et al. The effect of raloxifene on risk of breast cancer in postmenopausal women, results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. J. Am. Med. Assoc. 1999, 281, 2189-2197.
87. Veronesi, U.; de Palo, G.; Marubini, E.; Costa, A.; Formelli, F.; Mariani, L.; Decensi, A.; Camerini, T.; del Turco, M.R.; di Mauro, M.G.; et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J. Natl. Cancer Inst. 1999, 91, 1847-1856.
88. Hail, N., Jr.; Cortes, M.; Drake, E.N.; Spallholz, J.E. Cancer chemoprevention: A radical perspective. Free Rad. Biol. Med. 2008, 45, 97-110.
89. Kelloff, G.J.; Sigman, C.C.; Greenwald, P. Cancer chemoprevention: Progress and promise. Eur. J. Cancer 1999, 35, 2031-2038.
90. Kakizoe, T. Chemoprevention of cancer-Focusing on clinical trials. Jpn. J. Clin. Oncol. 2003, 33, 421-442.
91. Park, E.J.; Pezzuto, J.M. Botanicals in cancer chemoprevention. Cancer Metast. Rev. 2002, 21, 231-255.
92. Stan, S.D.; Kar, S.; Stoner, G.D.; Singh, S.V. Bioactive food components and cancer risk reduction. J. Cell. Biochem. 2008, 104, 339-356.
93. Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 2007, 70, 461-477.
94. Blunt, J.W.; Copp, B.R.; Munro, M.H.G.; Northcote, P.T.; Prinsep, M.R. Marine natural products. Nat. Prod. Rep. 2011, 28, 196-268.
95. Dumontet, C.; Jordan, M.A. Microtubule-binding agents: A dynamic field of cancer therapeutics. Nat. Rev. Drug. Discov. 2010, 17, 790-803.
96. Gullett, N.P.; Ruhul Amin, A.R.; Bayraktar, S.; Pezzuto, J.M.; Shin, D.M.; Khuri, F.R.; Aggarwal, B.B.; Surh, Y.J.; Kucuk, O. Cancer prevention with natural compounds. Semin. Oncol. 2010, 37, 258-281.
97. Hickford, S.J.; Blunt, J.W.; Munro, M.H. Antitumour polyether macrolides, four new halichondrins from the New Zealand deep-water marine sponge Lissodendoryx sp. Bioorg. Med. Chem. 2009, 17, 2199-2203.
98. Aoki, S.; Cao, L.; Matsui, K.; Rachmat, R.; Akiyamac, S.; Kobayashia, M. Kendarimide A, a novel peptide reversing P-glycoprotein-mediated multidrug resistance in tumor cells, from a marine sponge of Haliclona sp. Tetrahedron 2004, 60, 7053-7059.
99. Thomas, T.R.A.; Kavlekar, D.P.; LokaBharathi, P.A. Marine Drugs from Sponge-Microbe Association-A Review. Mar. Drugs 2010, 8, 1417-1468.
100. Rodriguez, A.D.; Martinez, N. Marine antitumor agents, 14-deoxycrassin and pseudoplexaurol, new cembranoid diterpenes from the Caribbean gorgonian Pseudoplexaura porosa. Experientia 1993, 49, 179-181.
101. Olano, C.; Méndez, C.; Salas, J.A. Antitumor Compounds from Marine Actinomycetes. Mar. Drugs 2009, 7, 210-248.
102. Hassan, H.M.; Khanfar, M.A.; Elnagar, A.Y.; Mohammed, R.; Shaala, L.A.; Youssef, D.T.A.; Hifnawy, M.S.; Sayed, K.A.E. Pachycladins A-E, prostate cancer invasion and migration inhibitory Eunicellin-based diterpenoids from the red sea soft coral Cladiella pachyclados. J. Nat. Prod. 2010, 73, 848-853.
103. Luqman, S.; Pezzuto, J.M. NFkappa B: A promising target for natural products in cancer chemoprevention. Phytother. Res. 2010, 24, 949-963.
104. Karin, M. Nuclear factor-kappa B in cancer development and progression. Nature 2006, 441, 431-436.
105. Crowell, J.A.; Steele, V.E.; Fay, J.R. Targeting the AKT protein kinase for cancer chemoprevention. Mol. Cancer Therap. 2007, 6, 2139-2148.
106. Andersen, J.N.; Sathyanarayanan, S.; di Bacco, A.; Chi, A.; Zhang, T.; Chen, A.H.; Dolinski, B.; Kraus, M.; Roberts, B.; Arthur, W.; et al. Pathway-based identification of biomarkers for targeted therapeutics, Personalized oncology with PI3K pathway inhibitors. Sci. Transl. Med. 2010, 2, 43-55.
107. Asolkar, R.N.; Freel, K.C.; Jensen, P.R.; Fenical, W.; Kondratyuk, T.P.; Park, E.J.; Pezzuto, J.M. Arenamides A-C, cytotoxic NF kappa B inhibitors from the marine actinomycetes Salinispora arenicola. J. Nat. Prod. 2009, 72, 396-402.
108. Schumacher, M.; Cerella, C.; Eifes, S.; Chateauvieux, S.; Morceau, F.; Jaspars, M.; Dicato, M.; Diederich, M. Heteronemin, a spongean sesterterpene, inhibits TNF alpha-induced NF-kappa B activation through proteasome inhibition and induces apoptotic cell death. Biochem. Pharmacol. 2010, 79, 610-622.
109. Edwards, V.; Benkendorff, K.; Young, F. Marine Compounds Selectively Induce Apoptosis in Female Reproductive Cancer Cells but Not in Primary-Derived Human Reproductive Granulosa Cells. Mar. Drugs 2012, 10, 64-83.
110. Oh, H.; Jensen, P.R.; Murphy, B.T.; Fiorilla, C.; Sullivan, J.F.; Ramsey, T.; Fenical, W. Cryptosphaerolide, a cytotoxic Mcl-1 inhibitor from a marine-derived ascomycete related to the genus Cryptosphaeria. J. Nat. Prod. 2010, 73, 998-1001.
111. Dias, N.; Vezin, H.; Lansiaux, A.; Bailly, C. Topoisomerase Inhibitors of Marine Origin and Their Potential Use as Anticancer Agents. Top. Curr. Chem. 2005, 253, 89-108.
112. Bonnard, I.; Bontemps, N.; Lahmy, S.; Banaigs, B.; Combaut, G.; Francisco, C.; Colson, P.; Houssier, C.; Waring, M.J.; Bailly, C. Binding to DNA and cytotoxic evaluation of ascididemin, the major alkaloid from the Mediterranean ascidian Cystodytes dellechiajei. Anticancer Drug Des. 1995, 10, 333-346.
113. Dassonneville, L.; Wattez, N.; Baldeyrou, B.; Mahieu, C.; Lansiaux, A.; Banaigs, B.; Bonnard, I.; Bailly, C. Inhibition of topoisomerase II by the marine alkaloid ascididemin and induction of apoptosis in leukemia cells. Biochem. Pharmacol. 2000, 60, 527-537.
114. Tardy, C.; Facompré, M.; Laine, W.; Baldeyroua, B.; arca-Gravalosb, D.; Franceschb, A.; Mateob, C.; Pastorb, A.; Jiménezb, J.A.; Manzanares, I.; et al. Topoisomerase I-mediated DNA cleavage as a guide to the development of antitumor agents derived from the marine alkaloid lamellarin D, triester derivatives incorporating amino acid residues. Bioorg. Med. Chem. 2004, 12, 1697-1712.
115. Ballot, C.; Kluza, J.; Martoriati, A.; Nyman, U.; Formstecher, P.; Joseph, B.; Bailly, C.; Marchetti, P. Essential role of mitochondria in apoptosis of cancer cells induced by the marine alkaloid Lamellarin D. Mol. Cancer Ther. 2009, 8, 3307-3317.
116. Schyschka, L.; Rudy, A.; Jeremias, I.; Barth, N.; Pettit, G.R.; Vollmar, A.M. Spongistatin 1: A new chemosensitizingmarine compoundthat degrades XIAP. Leukemia 2008, 22, 1737-1745.
117. Shin, H.J.; Jeong, H.S.; Lee, H.S.; Park, S.K.; Hwan, M.K.; Ho, J.K. Isolation and structure determination of streptochlorin, an antiproliferative agent from a marine-derived Streptomyces sp. 04DH110. J. Microbiol. Biotech. 2007, 17, 1403-1406.
118. Choi, I.K.; Shin, H.J.; Lee, H.S.; Kwon, H.J. Streptochlorin, a marine natural product, inhibits NF-. B activation and suppresses angiogenesis in vitro. J. Microbiol. Biotech. 2007, 17, 1338-1343.
119. Park, C.; Shin, H.J.; Kim, G.Y.; Kwon, T.K.; Nam, T.J.; Kim, S.K.; Cheong, J.; Choi, I.W.; Choi, Y.H. Induction of apoptosis by streptochlorin isolated from Streptomyces sp. in human leukemic U937 cells. Toxicol. In Vitro 2008, 22, 1573-1581.
120. Ali, M.S.; Jahangir, M.; Saleem, M.; Pervez, M.K.; Hameed, S.; Ahmad, V.U. Metabolites of marine algae collected from Karachi-coasts of Arabian sea. Nat. Prod. Sci. 2000, 6, 61-65.
121. Rice-Evans, C.A.; Miller, N.J.; Paganga, G. Antioxidant properties of phenolic compounds. Trends Plant Sci. 1997, 2, 152-159.
122. Maegawa, M.; Yokohama, Y.; Aruga, Y. Critical light conditions for young Ecklonia cava and Eisenia bicyclis with reference to photosynthesis. Hydrobiologia 1987, 151, 447-455.
123. Kong, S.C.; Kim, A.J.; Yoon, Y.N.; Kim, S.K. Induction of apoptosis by phloroglucinol derivative from Ecklonia Cava in MCF-7 human breast cancer cells. Food Chem. Toxicol. 2009, 47, 1653-1658.
124. Qin, C.; Du, Y.; Xiao, L.; Li, Z.; Gao, X. Enzymic preparation of water-soluble chitosan and their antitumor activity. Int. J. Biol. Macromol. 2002, 31, 111-117.
125. Lee, H.S.; Ryua, B.; Je, Y.J.; Kim, S.K. Diethylaminoethyl chitosan induces apoptosis in HeLa cells via activation of caspase-3 and p53 expression. Carbohydr. Polym. 2011, 84, 571-578.
126. Yamasaki-Miyamoto, Y.; Yamasaki, M.; Tachibana, H.; Yamada, K. Fucoidan Induces Apoptosis through Activation of Caspase-8 on Human Breast Cancer MCF-7 Cells. J. Agric. Food Chem. 2009, 57, 8677-8682.